Showing results (1-10 of 27) with videos related to
Sort By:
Pageof 3
Expert Opinion on Pharmacotherapy|July 31, 2007
A comparative evaluation of properties and clinical efficacy of the echinocandinsRose Kim, Deborah Khachikian, Annette C ReboliExpert Review of Anti-Infective Therapy|February 3, 2007
Anidulafungin: a new echinocandin for candidal infectionsPola de la Torre, Annette C ReboliCore Evidence|March 6, 2014
Micafungin: an evidence-based review of its place in therapyPola de la Torre, Annette C ReboliExpert Opinion on Pharmacotherapy|August 20, 2008
Anidulafungin: a drug evaluation of a new echinocandinJomy M Joseph, Rose Kim, Annette C ReboliFuture Microbiology|December 17, 2008
Anidulafungin: a novel echinocandin for candida infectionsPola de la Torre, Daniel K Meyer, Annette C ReboliInfectious Diseases (London, England)|March 27, 2015
Incidence and mortality of sepsis, severe sepsis, and septic shock in intensive care unit patients with candidemiaKevin Ng, Christa Schorr, Annette C Reboli, et al.Journal of Clinical Microbiology|October 9, 2003
Decreased vancomycin susceptibility of coagulase-negative staphylococci in a neonatal intensive care unit: evidence of spread of Staphylococcus warneriKimberly J Center, Annette C Reboli, Robin Hubler, et al.Pharmacoeconomics|May 20, 2011
Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patientsAnnette C Reboli, Coleman Rotstein, Daniel H Kett, et al.Critical Care (London, England)|October 27, 2011
Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasisDaniel H Kett, Andrew F Shorr, Annette C Reboli, et al.Pageof 3